At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Flosealdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery
In Brief
An observational study evaluating Floseal for Blood Loss. Completed, enrolled 300 participants across 1 site.
Detailed Summary
Perioperative variables that can be used to create a bundled approach quality improvement protocol to minimize blood loss in spine surgery will be evaluated using retrospective data collection and multivariate analysis of previously performed spinal surgeries at Johns Hopkins Hospital. In particular the investigators are interested in determining whether FloSeal® contributes towards increased control over perioperative bleeding compared to other hemostatic agents for potential inclusion in a future bundled approach.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Loss
CountriesUnited States
CollaboratorsBaxter Healthcare Corporation
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedAug 2019
Primary CompletionMar 2022
TodayJul 2026
First PostedAug 15, 2019
Enrollment StartJun 18, 2019
Primary CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.9 years ago
Interventions
Flosealdevice
Hemostatic agent